Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies-Reference-Cited by-同舟云学术

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

Published:2011-06-20 Issue:27 Volume:108 Page:11187-11192
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Schaefer W.,Regula J. T.,Bahner M.,Schanzer J.,Croasdale R.,Durr H.,Gassner C.,Georges G.,Kettenberger H.,Imhof-Jung S.,Schwaiger M.,Stubenrauch K. G.,Sustmann C.,Thomas M.,Scheuer W.,Klein C.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference33 articles.

1. Therapeutic antibodies for autoimmunity and inflammation

2. Recombinant approaches to IgG-like bispecific antibodies

3. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

4. Design and production of novel tetravalent bispecific antibodies

Cited by 384 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis;Pharmacological Research;2024-10

2. Bispecific Antibodies Provide Broad Neutralization of Emerging Beta-Coronaviruses by Targeting ACE2 and Viral Spikes;Emerging Microbes & Infections;2024-09-11

3. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B;Antiviral Research;2024-09

4. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors;Molecular Diagnosis & Therapy;2024-08-22

5. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs;Cancer Immunology, Immunotherapy;2024-08-09